🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating The Role Of Montelukast In Management Of Acute Bronchiolitis

RecruitingPhase 2Ages 4 Weeks - 2 YearsAllPakistan Institute of Medical Sciences
NCT07770464 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the role of Montelukast in management of acute Bronchiolitis in indoor patient and how this drug shortens the duration of admission and improves symptoms

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria * Age 4 weeks to 2 years * Both genders * Duration of respiratory symptoms less than 4 days * Clinical diagnosis of acute bronchiolitis according to the operational definition provided in the study protocol Exclusion Criteria * History of asthma * Previous hospital admissions for respiratory illness * Use of asthma medications * Congenital heart disease * Bronchopulmonary dysplasia * Immunodeficiency * Immunosuppression * Radiological evidence of pneumonia, including infiltrates or patches on chest X-ray
💊

What it tests

  • Montelukast
  • Placebo
📍

Where

1 site
Pakistan Institute of Medical Sciences, Islamabad
Islamabad, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy